Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBITDA MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginReturn on AssetsReturn on EquityReturn on Sales

Summit Therapeutics (SMMT) Return on Capital Employed (2023 - 2024)

Summit Therapeutics (SMMT) has disclosed Return on Capital Employed for 2 consecutive years, with 0.53% as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Return on Capital Employed rose 267.0% year-over-year to 0.53%, compared with a TTM value of 0.53% through Dec 2024, up 267.0%, and an annual FY2024 reading of 0.81%, up 66.0% over the prior year.
  • Return on Capital Employed was 0.53% for Q4 2024 at Summit Therapeutics, up from 0.54% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.53% in Q4 2024 and bottomed at 5.17% in Q3 2023.